Altimmune公司2025年季度报告

FORM10-Q (Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE For the quarterly period endedMarch 31, 2025or ☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGEACT OF 1934 For the transition period fromtoCommission file number001-32587 Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of theSecurities Exchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant was required to filesuch reports), and (2)has been subject to such filing requirements for the past 90days.Yes⌧No◻ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule405 of RegulationS-T (§232.405 of this chapter) during the preceding 12months (or for such shorter Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transitionperiod for complying with any new or revised financial accounting standards provided pursuant to Section13(a)of the ExchangeAct.◻ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Act).Yes☐No⌧As of May9, 2025 there were 81,106,973 shares of the registrant’s common stock, par value $0.0001 per share,outstanding. ALTIMMUNE,INC.TABLE OF CONTENTS PARTI. FINANCIAL INFORMATION Item1.Financial Statements Consolidated Balance Sheets as of March 31, 2025 (unaudited) and December 31,2024Consolidated Statements of Operations and Comprehensive Loss for the threemonths ended March 31, 2025 and 2024 (unaudited) Consolidated Statements of Changes in Stockholders’ Equity for the three months ended March 31, 2025 and 2024 (unaudited)Consolidated Statements of Cash Flows for the three months ended March 31, 2025and 2024 (unaudited)Notesto Consolidated Financial Statements (unaudited) PARTII. OTHER INFORMATION Item1.Legal ProceedingsItem1A.Risk FactorsItem2.Unregistered Sales of Equity Securities and Use of ProceedsItem3.Defaults Upon Senior SecuritiesItem4.Mine Safety DisclosuresItem5.Other InformationItem6.ExhibitsSignatures ALTIMMUNE,INC.CONSOLIDATED BALANCE SHEETS(In thousands, except share and per-share amounts) ALTIMMUNE,INC.CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS ALTIMMUNE,INC.CONSOLIDATED STATEMENTS OF CASH FLOWS ALTIMMUNE,INC.NOTESTO CONSOLIDATED FINANCIAL STATEMENTS 1. Nature of Business and Basis of Presentation Nature of Business Altimmune,Inc., headquartered in Gaithersburg, Maryland, United States, together with itssubsidiaries (collectively, the “Company” or “Altimmune”) is a late clinical stage biopharmaceutical The Company is a late clinical-stage biopharmaceutical company focused on developingnovelpeptide-based therapeutics for liver and cardiometabolic diseases. The Company’s leadprogram is pemvidutide (formerly known as ALT-801), a GLP-1/glucagon dual receptor agonist forthe treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), obesity, Alcohol UseDisorder (“AUD”) and Alcohol Liver Disease (“ALD”). The Company may also pursue additionalindications for pemvidutide that leverage its differentiated clinical profile. Since its inception, theCompany has devoted substantially all of its efforts to business planning, research and development, Basis of Presentation The accompanying unaudited consolidated financial statements are prepared pursuant to therulesand regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interimfinancial reporting. Accordingly, they do not include all of the information and disclosures requiredby accounting principles generally accepted in the United States (“U.S. GAAP”) for completeconsolidated financial statements and should be read in conjunction with the audited consolidatedfinancial statements for theyear ended December 31, 2024, included in the Annual Report onForm10-K, which was filed with the SEC on February 27, 2025. In the opinion of management, the The accompanying unaudited consolidated financial statements include the accounts of theCompany and its wholly owned subsidiaries. All significant intercompany accounts and transactions The accompanying unaudited consolidated financial statements have been prepared on thebasis of continuity of operations, realization of assets, and the satisfaction of liabilities in the ordinarycourseof business. The financial statements do not include any adjustments relating to the 2. Summary of Significant Accounting Policies During the three months ended March 31, 2025, there have been no significant changes tothe Company’s summary of significant accounting policies contained